Kytopen was founded by Cullen Buie, Paulo Garcia in 2017.

Who are Kytopen's investors?

Kytopen's investors include Bantam Group, Horizons Ventures, MassVentures, Selvedge Venture, TBD Angels, Telegraph Hill Partners, The Engine Ventures, Alexandria and 1 more.

How much funding has Kytopen raised?

Kytopen has disclosed $52.7M raised across 5 of its 6 known rounds.

Where is Kytopen headquartered?

Kytopen is headquartered in Cambridge, US.

Kytopen

Cambridge, US · Founded 2017 · Delaware corporation · 10 known investors

Find your way into Kytopen

1,866 people in our graph share verified history with the Kytopen team — schools, employers, funds. One of them is your warm intro.

Wesley Chanunlockedknows Michael Chiu · together at Massachusetts Institute of Technology (overlapped)

×5knows the team · via Massachusetts Institute of Technology

×2knows the team · via Stanford University

knows the team · via MIT Sloan School of Management

knows the team · via Virginia Tech

knows the team · via Massachusetts Institute of Technology (MIT)

Kytopen develops non-viral gene delivery technology called Flowfect that combines fluid flow with electric fields to deliver payloads such as mRNA, DNA, and CRISPR Cas9 RNP into cells for high-throughput transfection. Its platforms serve cell therapy researchers and developers, supporting drug discovery, process optimization, and scaling from small-volume experiments to manufacturing.

Biotech Deep Tech Hardware

Founders & leadership

Kytopen was founded in 2017 by Cullen Buie and Paulo Garcia.

Cullen Buie inCo-FounderCullen Buie is director of Kytopen and has research expertise in electrokinetics, electrochemistry, fluid mechanics, and microscale engineering applied to biotechnology.

Paulo Garcia inCo-Founder & AdvisorPaulo Garcia holds a Ph.D. in biomedical engineering from Virginia Tech - Wake Forest University, where his research focused on pulsed electric field applications for minimally invasive treatment. He completed postdoctoral training and led biomanufacturing research in the Mechanical Engineering department at MIT, where he co-founded Kytopen to develop non-viral gene delivery technology; he later became CEO and President of BLASTID, a Harvard University spinout developing diagnostic platforms from the ARPA-H DARTS program.

Michael Chiu inChief Executive OfficerMichael Chiu founded and previously led a VC-backed startup through a successful exit, and has held general management roles at large technology companies including oversight of a business unit generating over $60M in revenue. He brings experience in product development, commercialization, and cross-functional operations including engineering, supply chain, and marketing.

Julio VegaMr. Vega is the Secretary of the Issuer.

Board

Paxton Major inBoard Director2023–2026Managing Director at Northpond Ventures

Ann DeWitt inBoard directorGeneral Partner at The Engine Ventures

Paul WottonBoard director

Investors · 10

Bantam GroupWestwood

Horizons VenturesHong Kong · $1M – $110M

MassVenturesWaltham · $250K – $500K

Selvedge VentureLondon

TBD AngelsNew York

Telegraph Hill PartnersSan Francisco · $2M – $8M

The Engine VenturesCambridge

AlexandriareportedPasadena

Northpond Venturesreported · 2 sourcesBethesda · $100K – $5M

Also in the syndicate · 1

The Engine

Funding

SEC filings, press & company announcements

$52.7M disclosed across 5 of 6 rounds · 2019–2026

Undisclosed amountSeries BApr 2026 · 3 sources
Telegraph Hill Partners (lead)
Source ↗

▶$7.1MraisedFeb 2025 · 13 investors · Biotechnology

Rule 506(b)